March 2010 Br J Cardiol 2010;17:76–80
Martin R Cowie, Paul O Collinson, Henry Dargie, FD Richard Hobbs, Theresa A McDonagh, Kenneth McDonald, Nigel Rowell
(more…)
November 2008 Br J Cardiol 2008;15: 322–5
Amam C Mbakwem, Olatunji F Aina
Introduction A large number of studies have documented a high rate of co-occurrence of psychiatric morbidity and chronic medical conditions, such as bronchial asthma, diabetes, hypertension and heart disease.1,2Specifically, in heart failure (HF), psychiatric complications such as depression and anxiety are very common.3,4 In Africa, most especially Nigeria, HF is quite common with attendant high morbidity and mortality rates.5,6 Studies have shown that co-morbid psychiatric disorders delay recovery from HF, increasing length of hospital stay, with associated poorer prognosis and increased mortality.7,8 Despite the importance of co-morbid psy
September 2008 Br J Cardiol 2008;15:231-36
BJCardio editorial team
GISSI-HF shows benefit for PUFA in heart failure Two new studies from the Italian GISSI group show that n-3 polyunsaturated fatty acids (PUFA) supplementation improves morbidity and mortality in those with symptomatic heart failure, but statins don’t have any benefit in the same type of patients. The results were presented during a hotline session at the Congress and published simultaneously in The Lancet (Lancet 2008; DOI:10.1016/S0140-6736[08]61239-8, and Lancet 2008;DOI:10.1016/S0140-6736[08]61240-4). Long-term administration of PUFA reduced all-cause mortality by 9%, which the investigators say was a modest effect, and they also cut
September 2008 Br J Cardiol 2008;15:261-5
Timothy Bonnici, David Goldsmith
Introduction Renal artery stenosis (RAS), traditionally the preserve of the nephrologist, is a condition of increasing interest to the cardiologist. Ninety per cent of RAS is caused by atherosclerosis and the risk factors for renal atherosclerosis and coronary atherosclerosis are the same. Furthermore, the presence of RAS alters the prognosis of co-existent cardiac disease, most notably cardiac failure and ischaemic heart disease, both directly1–3 and via its sequelae of renal failure and hypertension. Finally, the treatments for the disease, both medical and interventional, are familiar to the cardiologist, who can employ much of the knowl
July 2008 Br J Cardiol 2008;15:179–80
Ahmet Fuat
A recent survey of primary care trusts (PCTs) in England found that only 26% currently offered or had previously offered natriuretic peptides for use in primary care.4 Clinicians and healthcare purchasers (PCTs in the UK) still harbour concerns about appropriate cut-offs, the extra cost of BNP/NT proBNP assays, which assay to use (BNP or NT proBNP/point-of-care or laboratory assay), lack of expedient referral pathways for patients with a raised BNP/NT proBNP level and absence of cost-benefit/effectiveness data from a prospective primary care study. Landmark studies such as the Hillingdon heart failure study5 confirmed the high negative predic
March 2008 Br J Cardiol 2008;15:101-5
Martin Duerden, Maggie Tabberer
(more…)
January 2008 Br J Cardiol 2008;15:6
Jim Moore
Setting an example The primary care-based heart failure service in Gloucestershire is now four years old and has promising data from its 2006 audit. The audit comprises data from all patients (n=524) with left ventricular systolic dysfunction managed by the service throughout 2006. Results showed all-cause mortality in this high-risk group of only 8.2%, with half of these patients dying at home. In the group of patients who had died during 2006, almost one third had previously discussed and indicated the place they wished to be cared for during the final phase of their illness, with the vast majority opting for home. In over 70% of these case
January 2008 Br J Cardiol 2008;15:35-9
Kiran CR Patel, Jennifer Prince, Seema Mirza, Lucy Edmonds, Rachel Duncan, Joanna Parry, Sally Jerome, John Wozniak, Nic Anfilogoff, Michael Frenneaux, Michael K Davies
Introduction Heart failure (HF) is common and is associated with a high morbidity and mortality. Forty per cent of patients with symptomatic left ventricular systolic dysfunction (LVSD) die within a year of diagnosis and 10% per annum thereafter, giving a five-year mortality rate of up to 70%.1 Estimates of the prevalence of symptomatic HF in the general European population range from 0.4–2%,2-4 with half of these patients suffering from LVSD and half from left ventricular diastolic dysfunction (LVDD).3,5 HF consumes nearly 2% of National Health Service (NHS) resources (a figure which will inevitably increase with the advent of relatively e
November 2007 Br J Cardiol 2007;14:275-79
Christopher Ward
Easily accessible routine clinical data are summarised that identify patients whose claims are most likely to succeed. Introduction Dr Christopher Ward The financial difficulties of the NHS, including those of cardiac services, are often highlighted in the medical press. However, patients’ financial problems are rarely addressed and the specific issue of helping heart failure patients to obtain their financial entitlements has never been discussed in the Journals. It is now widely accepted that patients with heart failure have similar needs for supportive and palliative care as do patients with cancer: to control physical and psychologica
July 2006 Br J Cardiol 2006;13:283
Yasmin Ismail, Elizabeth McNeill, Mandie Townsend, Thomas MacConnell
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits